Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

CAR-T Meeting 2021

Myeloma Patients Europe: collaborating on projects to benefit the myeloma community 2:49
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
CAR T-cells in adult ALL 4:13
CAR T-cells in adult ALL
Arnon Nagler • 1 Feb 2021
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
The journey of CAR-T therapy from hematological malignancies to solid tumors 2:47
The journey of CAR-T therapy from hematological malignancies to solid tumors
Concetta Quintarelli • 4 Feb 2021
NK-CAR immunotherapy: where are we now? 1:41
NK-CAR immunotherapy: where are we now?
Concetta Quintarelli • 4 Feb 2021
The importance of partnering with patient organizations 3:48
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
Highlights from the 3rd European CAR T-cell Meeting 1:08
Highlights from the 3rd European CAR T-cell Meeting
Anna Sureda • 9 Feb 2021
CAR T-cells in myeloma: patients’ perspective 1:52
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
Novel strategies to optimize CAR T-cell therapy 4:31
Novel strategies to optimize CAR T-cell therapy
Arnon Nagler • 1 Feb 2021
Management of CAR-T related side effects 1:50
Management of CAR-T related side effects
Ibrahim Yakoub-Agha • 4 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
Infection prevention in patients receiving CAR T-cells 3:19
Infection prevention in patients receiving CAR T-cells
Joshua Hill • 10 Feb 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:30
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
Cytopenias post-CAR T-cell therapy 4:10
Cytopenias post-CAR T-cell therapy
Ibrahim Yakoub-Agha • 4 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
Infectious complications after CAR T-cell therapy 2:02
Infectious complications after CAR T-cell therapy
Joshua Hill • 10 Feb 2021
  • 1
  • 2
  • 3
  • 4
  • Next
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy